2022-RA-440-ESGO  
**BRCA1/2 TESTING RATES IN EPITHELIAL OVARIAN CANCER: A FOCUS ON THE UNTESTED PATIENTS**

1Lieke Lanjouw, 2Marie-Jeanne Moutis, 3Joost Bart, 2Anja ter Elst, 2Lieke PV Berger, 4Annemiek H van der Hout, 5Naufil Alam, 1Geertruud H de Boek. 1Epidemiology, University Medical Center Groningen, Groningen, Netherlands; 2Obstetrics and Gynaecology, University Medical Center Groningen, Groningen, Netherlands; 3Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands; 4Genetics, University Medical Center Groningen, Groningen, Netherlands; 5AstraZeneca Pharmaceuticals LP, Cambridge, UK

10.1136/ijgc-2022-ESGO.979

**Introduction/Background** (Encore-but-modified/new-data). Since 2015, BRCA1/2 pathogenic variant (PV) testing is recommended for all epithelial ovarian cancer (EOC) patients in the Netherlands. Recently, recommendations shifted from germline testing to universal tumor testing and subsequent germline testing in those with BRCA1/2 tumor PVs (TPVs). Data on testing rates of these approaches and on characteristics of patients missing out on testing remain scarce. Therefore, we evaluated BRCA1/2 testing rates in EOC patients and compared rates of germline testing (performed from 2015 until mid-2018) versus tumor testing with germline testing only in those with TPVs (implemented mid-2018). Additionally, we delineated characteristics of patients who were less likely to receive BRCA1/2 testing.

**Methodology** A consecutive series of 250 patients diagnosed with EOC between 2016 and 2019 was included from the OncoLifeS databiobank of the University Medical Center Groningen. Testing rates were analyzed for the overall study population and by period of diagnosis to evaluate rates of germline testing (period I) and tumor-first testing (period II) separately. Characteristics of tested and untested patients were compared using the appropriate statistical test.

**Results** Median age was 67.0 years (interquartile range: 59.0–73.0) and 69.2% was diagnosed with high-grade serous carcinoma (HGSC). Overall, 80.4% of all patients had a known germline PV (GPV) status. In period I, 80.1% of all patients had a known GPV status and in period II this was 81.0%. Overall, and in period I and II separately, a significantly greater proportion of patients with HGSC was tested, as compared to those with non-HGSC (74.6% versus 23.9%; P=0.001).

**Conclusion** The results show that BRCA1/2 testing rates are suboptimal and suggest that clinicians may not be choosing to test EOC patients with non-HGSC, although guidelines recommend BRCA1/2 testing in all EOC patients. Suboptimal testing rates limit the optimization of care for EOC patients and counseling of potentially affected relatives.

---

2022-RA-641-ESGO  
**A FRAMEWORK FOR MANAGING INAPPROPRIATE REFERRAL TO THE GYNAECOLOGY RAPID ACCESS CLINIC**

Melin Dokmeci, Robert MacDemott. Obstetrics and Gynaecology, Dartford and Gravesham NHS Trust, Dartford, UK

10.1136/ijgc-2022-ESGO.980

**Introduction/Background** The UK National Institute for Health and Care of Excellence (NICE) has published guidance for suspected cancer referrals to help Primary Care doctors refer patients for further investigations. The threshold cancer probability for referral is set at 3%. Patients are then seen in rapid access clinics (RAC) in Secondary Care. Unfortunately, many referrals are inappropriate and this creates a burden in secondary care. These referrals also cause unnecessary anxiety to the patients. To improve the efficacy and effectiveness of the RAC, we identify inappropriate referrals and manage these patients in an alternative pathway. We provide timely feedback and education for staff working in Primary Care. Standardised letters have been developed for each type of inappropriate referral, which are sent to both the patient and the referring doctor.

**Methodology** A retrospective analysis of all suspected cancer referral forms sent to our unit between May 1st 2021 and April 31st 2022 was performed.

**Results** A total number of 958 suspected cancer referrals were made to our unit within the period of 12 months. These were triaged by a senior gynaecologist and 28% were deemed inappropriate. Of these inappropriate referrals, 15% were for suspicion of endometrial cancer, 7% were for ovarian cancer and 6% were for cervical, vulval and vaginal cancers grouped together. Breakthrough bleeding on Hormone Replacement Therapy (HRT) was the most common inappropriate referral (n=81). Other common reasons included: obviously benign lesions of the vulva, vagina and cervix, intermenstrual bleeding, postcoital bleeding, non-suspicious ovarian cysts, endometrial thickening, and isolated elevation of CA125. We have identified Primary Care doctors that are outliers and provided targeted education and training.

**Conclusion** We have identified common reasons for inappropriate referral and created an alternative pathway for these patients. Targeted education has been provided for Primary Care doctors. These measures have enabled the RAC to function more effectively.

---

2022-RA-667-ESGO  
**VAGINAL BRACHYTHERAPY - THE PATIENT JOURNEY**

Tatiana Rabin, Inbal Golomb, Dorin Berman, Hila Granot. Division of oncology, Radiotherapy Department, Tel Aviv Medical Center, Aviv, Israel

10.1136/ijgc-2022-ESGO.981

**Introduction/Background** Vaginal brachtherapy is frequently used in patients with endometrial cancer. Its role in prevention of local recurrence is substantial. Safe and effective use of vaginal brachtherapy requires dedicated personnel with specific training, skills, techniques, and patient education. Success of the treatment is a combination of professionalism including a positive experience for the patient leading to close cooperation and a smooth process. To ensure a less traumatic procedure, we developed a special approach to this category of patients giving special attention to the patients’ education.

**Methodology** Since 2018 when the brachtherapy service was established, we have developed a special and comprehensive approach tailored for every patient. During the first visit, each patient meets the following personnel: doctor, nurse, and brachtherapy coordinator. Each patient receives a detailed verbal, visual and written information regarding the whole process and a short guided ‘tour’ in the brachtherapy unit. We provide a supportive group facilitated by a social worker, sexologist and a psychologist. The brachtherapy treatment itself take place at the brachtherapy unit, separated from the rest of the department giving our patients a feeling of safety and confidence. The brachtherapy unit is joined with the Department of Radiation Oncology, and the brachtherapy treatment is delivered as a part of radiation therapy.
intimacy. The device we use for the treatment is heated at body temperature and during insertion, a special technique ensures painless tightening and stability in the body.

**Results** Since the location of the device in the body has an influence on the radiation dose to the adjacent organs, the patient’s position results in a reduction of dose to the rectum and bladder and decreases the rate of acute and late toxicity.

**Conclusion** Cooperation of our patients and techniques provides successful treatment planning and delivery while reducing radiotherapy dose to the organs at risk. This approach significantly reduces the level of anxiety, helps patients trust and cooperate with staff, complete treatment without interruptions and an overall better outcome.

**Methodology** In this multicentre non-inferiority trial, 316 women from 42 hospitals with FIGO stage IA/B endometrial cancer were randomly allocated to reduced FU (n=160) or usual FU care (n=156). The women completed questionnaires at baseline (after surgery), and after 6, 12 and 36 months. The primary outcome was satisfaction with care (PSQ-III) with a predefined noninferiority margin of 6 points (range 0–100). Mixed linear regressions were used.

**Results** 299 (95%) women completed the questionnaire at baseline; 291 (92%) at 6-months; 272 (86%) at 12 months and 222 (70%) at 36 months. During three years after treatment, women in the reduced FU group had a median of 3.5 [IQR 3.0–5.0] visits with their specialist/nurse compared to 7.0 [IQR 6.0–9.0] visits for women in the usual FU group. Overall satisfaction with care was similar in the reduced FU (M=82;SD=15) and usual FU (M=82;SD=13) group. At 6, 12 and 36 months, more patients (93/94/90%) in the reduced FU arm were satisfied with their FU schedule than patients in usual FU arm (79/78/82%). Nine women in the reduced FU group and five in the usual FU group developed a recurrence (n.s.).

**Conclusion** Women receiving reduced follow-up care were just as satisfied with their care as those receiving follow-up care according to Dutch guidelines. Compared to usual care, women in the reduced care group had fewer medical visits and, at the same time, more often reported being satisfied with this reduced frequency.

**Abstract 2022-RA-667-ESGO**

**THE ENSURE TRIAL FOR WOMEN WITH EARLY-STAGE ENDOMETRIAL CANCER: A RANDOMIZED CONTROLLED TRIAL COMPARING THE EFFECT OF A REDUCED VERSUS USUAL FOLLOW-UP SCHEDULE ON PATIENT SATISFACTION, HEALTH CARE USE, AND DISEASE PERCEPTIONS**

Nicole PM Ezendam, Belle H de Rooij, Carien L Creutzberg, Roy F Kroeswagen, Luc RCW van Lonkhuijzen, Mirjam JA Apperloo, Kees Gerestein, Astrid Baalbergen, Dorin Boll, Caroline Vos, Lonneke V van de Poll-Franse.

11 Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
9 Dorry Boll, 10 M Caroline Vos, 11 Lonneke V van de Poll-Franse.

1, 2 Nicole PM Ezendam, 1, 2 Belle H de Rooij, 3 Carien L Creutzberg, 4 Astrid Baalbergen, 5 Dorin Boll, 10 M Caroline Vos, 11 Lonneke V van de Poll-Franse. 1 Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands; 2 Tilburg University, Tilburg, Netherlands; 3 Leiden University Medical Center, Leiden, Netherlands; 4 Maastricht University Medical Center, Maastricht, Netherlands; 5 Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands; 6 Medical Centre Leeuwarden, Leeuwarden, Netherlands; 7 Universitair Medisch Centrum Utrecht, Utrecht, Netherlands; 8 Reinier de Graaf Hospital, Delft, Netherlands; 9 Catharina hospital, Eindhoven, Netherlands; 10 Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; 11 Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

**Introduction/Background** The aim of the study was to assess the efficacy of prehabilitation program based on six-minute walking test (6MWT) introduced to ovarian cancer patient.

**Methodology** 32 ovarian cancer patients FIGO III were included in the study. Participants were randomly assigned to controls (n=24) and prehabilitation group (n=28). 3 weeks before surgery, prehabilitation group were tested for Muscle Action Potential (MAP) using LUNA EMG and with 6MWT (to calculate VO2max), and were instructed to perform physical training at home. All patients were assessed one day before surgery – laboratory tests, LUNA, and 6MWT were performed. Changes in MAP and VO2max were used as objective measurement of compliance with physical prehabilitation. Mean time to resume physical activity, hospital duration and peri/postoperative complication rate were analyzed.

**Results** The mean age in prehabilitation group and controls was 58.2±11.7 vs 59.2±12.1, respectively. No significant difference between groups in VO2max measured one day before surgery was noted – 15.3 vs 14.8 mL/kg-1·min-1, respectively. The mean maximal MAP (LUNA) was 144.8 mV and 87.4 mV, respectively. The mean hospital stay was 5.89±2.9 and 7.0 [IQR 6.0–9.0] visits for women in the usual FU group. Overall satisfaction with care was similar in the reduced FU (M=82;SD=15) and usual FU (M=82;SD=13) group. At 6, 12 and 36 months, more patients (93/94/90%) in the reduced FU arm were satisfied with their FU schedule than patients in usual FU arm (79/78/82%). Nine women in the reduced FU group and five in the usual FU group developed a recurrence (n.s.).

**Conclusion** Women receiving reduced follow-up care were just as satisfied with their care as those receiving follow-up care according to Dutch guidelines. Compared to usual care, women in the reduced care group had fewer medical visits and, at the same time, more often reported being satisfied with this reduced frequency.

**2022-RA-732-ESGO**

**PREHABILITATION PROGRAM IN OVARIAN CANCER PATIENTS – TOWARDS MORE OBJECTIVE MEASUREMENT OF COMPLIANCE – PRELIMINARY RESULTS**

Krzysztof Nowosielski, Marcin Zebalski, Paulina Szotek, Wojciech Szancki. Department of Gynecology, Obstetrics and Gynecological Oncology, Medical University of Silesia, University Clinical Center, Katowice, Poland.

10.1136/ijgc-2022-ESGO.983